Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Interpore's bone void filler:

This article was originally published in Clinica

Executive Summary

The US FDA has cleared Interpore Cross International's bone void filler, BonePlast. The biocompatible, calcium sulphate-based material that resorbs and is replaced with bone during the healing process may be used in bony voids of the skeletal system, such as the extremities, spine and pelvis. It has a mouldable, dough-like consistency and remains workable for around six to eight minutes before hardening. The Irvine, California-based company plans to begin selling the product later this year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079462

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel